Biotech Values

[jbog]

During FY4Q15 (which predates any ABBV HCV sales in Japan), ENTA received V-Pak/Technivie/Viekirax royalties from ABBV at an annualized rate of $57M.

While these numbers might have some upside they certainly are dismal compared to the >$200m that was projected.

The market won't be there.